Tempest Therapeutics share price logo

Tempest Therapeutics

NASDAQ: TPST

$0.90

-0.31

(-25.63%)

Live

as on

Tempest Therapeutics Stock Performance

as on September 18, 2026 at 1:09 am IST

  • Day's Low

    Day's High

    $0.86
    $1.07
    downward going graph

    4.43%

    Downside

    18.90%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.74
    $6.12
    downward going graph

    17.41%

    Downside

    579.52%

    Upside

    downward going graph

Tempest Therapeutics share price movements today

Previous Close
$1.21
Open
$1.07
Volume
2.0M
Market Cap
$12.5M
Day's Low - High
$0.86 - $1.07
52 Week Low - High
$0.74 - $6.12

Tempest Therapeutics Historical Returns

1 Month Return
+ 7.08 %
3 Month Return
-3.2 %
1 Year Return
-74.74 %
3 Year Return
-61.76 %
5 Year Return
-98.77 %

Tempest Therapeutics Stock Fundamentals & Key Indicators

Check Tempest Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$12.5M

EPS (TTM)

-4.48

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.17

Industry PE ratio

-2.36

PEG Ratio

-0.0068644323864200385

EBITDA

-40.3M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-1270.11%

Tempest Therapeutics Stock Valuation

Track how Tempest Therapeutics P/E has moved over time to understand its valuation trends.

Tempest Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-7.23x)

December 31, 2024

Industry (-2.36x)

December 31, 2025

Today (-0.45x)

December 31, 2025

Highest (-0.05x)

December 31, 2021

LowHigh

Today’s Price to Earnings Ratio: -0.45x

Tempest Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Tempest Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$12.5M-98.77%-0.170.00%0.00%
BUY$43.9B527.35%NA0.00%0.00%
BUY$130.4B172.58%29.7186.04%0.00%
BUY$57.4B-66.14%-18.02-12.57%0.00%
BUY$81.7B18.83%18.4884.86%0.48%

Stock Returns calculator for Tempest Therapeutics Stock including INR - Dollar returns

The Tempest Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Tempest Therapeutics investment value today

Current value as on today

₹20,507

Returns

-₹79,493

(-79.49%)

Returns from Tempest Therapeutics Stock

-₹81,213 (-81.21%)

Dollar Impact

₹1,720 (+1.72%)

Analyst Recommendation on Tempest Therapeutics Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Tempest Therapeutics. Average target price of $11

Tempest Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Tempest Therapeutics.

What analysts predicted

91.82%UPSIDE

Target Price

$11

Current Price

$0.8999

Analyzed by

12 Analysts

Target

$11.00

Tempest Therapeutics target price $11, a slight upside of 91.82% compared to current price of $0.8999. According to 12 analysts rating.

Indian Investors' Interest in Tempest Therapeutics Stock

Search interest for Tempest Therapeutics Stock has increased by 834% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:834% versus previous 30 day period

Tempest Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
0
-
-
-22
-
Operating Income
-7
-9
-10
-13
-10
-7
-3
-4
-27
-5
EBITDA
-7
-9
-10
-13
-10
-7
-3
-3
-27
-5
Interest Expense
0
0
0
0
0
0
-
-
0
-
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-7
-9
-10
-13
-10
-7
-3
-4
-27
-5
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-7
-9
-10
-13
-10
-7
-3
-4
-27
-5
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Tempest Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
-
-
-
-
-
-
-
-
Gross Profit
0
0
-1
0
-
-
-
0
-
Operating Income
-20
-23
-45
-19
-26
-34
-29
-42
-26
EBITDA
-84
-27
-43
-18
-26
-33
-27
-40
-25
Interest Expense
-
0
-
-
1
1
1
1
0
Depreciation
0
0
1
0
0
0
0
0
0
Income Before Tax
-84
-27
-44
-19
-28
-35
-29
-41
-26
Income Tax Expense
0
0
-
-
-
-
-
-
-
Net Income
-84
-27
-44
-19
-28
-35
-29
-41
-26
Net Profit Margin
90.51%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Tempest Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-7
-9
-10
-13
-10
-7
-3
-4
-27
-5
Operating Cash Flow
-7
-5
-10
-10
-8
-8
-6
-3
-7
-2
Investing Cash Flow
0
0
0
0
-
-
-
-
-
-
Financing Cash Flow
0
4
1
17
0
1
0
3
1
1
Change in Cash
-6
-1
-8
7
-8
-7
-6
0
-5
-1

Tempest Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-84
-27
-44
-19
-28
-35
-29
-41
-26
Operating Cash Flow
-20
-23
-41
-19
-25
-31
-27
-33
-26
Investing Cash Flow
0
1
3
0
0
0
0
0
-
Financing Cash Flow
-4
78
26
34
59
11
35
24
4
Change in Cash
-26
55
-9
15
33
-20
8
-8
-22

Mutual Funds that own Tempest Therapeutics Stock

Check out the Mutual Funds with significant holdings in Tempest Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
1.463683%
233888
Fidelity Concord Street Trust
0.226754%
36234

Global Institutional Holdings in Tempest Therapeutics

Funds
Holdings
Brad Bolzon
1.69%
Vanguard
1.46%

Tempest Therapeutics News & Key Events

  • img

    Today's Timeline - 15 September

    Wed, 01:40 AM

    -

    Tempest Therapeutics enters exclusive option agreement with Hebei Senlang for licensing CAR-T product candidates.

    Wed, 02:02 AM

    -

    Tempest Therapeutics raises $2.5 million through private placement of warrants and common stock.

Insights on Tempest Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, TPST stock has moved up by 50.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 27.1% return, outperforming this stock by 88.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 482.5% return, outperforming this stock by 557.2%

About Tempest Therapeutics

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
OrganisationTempest Therapeutics
Headquarters2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
IndustryBiotechnology
CEODr. Matthew Angel Ph.D.
E-voting on sharesClick here to vote

Key Management of Tempest Therapeutics

Name

Title

Dr. Matthew Angel Ph.D.

President, CEO & Director

Mr. Nicholas J. Rossettos CPA, M.B.A.

CFO, Principal Financial & Accounting Officer, Treasurer and Corporate Secretary

Dr. Andrew Fang Ph.D.

Head of Business Development

FAQs

What is Tempest Therapeutics share price today?

Tempest Therapeutics share price today is $0.90 as on . Tempest Therapeutics share today touched a day high of $1.07 and a low of $0.86.

What is the 52 week high and 52 week low for Tempest Therapeutics share?

Tempest Therapeutics share touched a 52 week high of $6.12 on and a 52 week low of $0.74 on . Tempest Therapeutics stock price today i.e. is trending at $0.90,which is 85.28% down from its 52 week high and 21.08% up from its 52 week low.

What is Tempest Therapeutics's market capitalisation today?

Tempest Therapeutics market capitalisation is $0.00T as on .

How to invest in Tempest Therapeutics Stock (TPST) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Tempest Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Tempest Therapeutics Shares that will get you 1.6669 shares as per Tempest Therapeutics share price of $0.90 per share as on September 17, 2026 at 7:39 pm IST.

What is the minimum amount required to buy Tempest Therapeutics Stock (TPST) from India?

Indian investors can start investing in Tempest Therapeutics (TPST) shares with as little as ₹95.93 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹959.30 in Tempest Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Tempest Therapeutics share’s latest price of $0.90 as on September 17, 2026 at 7:39 pm IST, you will get 11.1123 shares of Tempest Therapeutics. Learn more about fractional shares .

What are the returns that Tempest Therapeutics has given to Indian investors in the last 5 years?

Tempest Therapeutics stock has given -98.77% share price returns and 29.9% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?